[Comparative radioligand analysis of gene-engineered and human hypophyseal somatotropic hormones].
Somatogen, a human somatotropic hormone (HSH) prepared with the use of gene engineering (genHSH) does not differ from the highly purified substance of hypophysial hormone (hypHSH) in affinity to the antibodies produced on hypHSH and to the membrane receptor of the rabbit liver. 50 per cent inhibition of 125I hypHSH binding to the antibodies was observed at somatogen concentration of 8.2 ng/ml and hypHSH concentration of 7.9 ng/ml. The affinity constants of somatogen and hypHSH to the receptor amounted to 3.8 X 10(9) and 3.6 X 10(9) M-1, respectively. Somatogen for injections as a medicine contains 94.6 per cent of the hormone monomer and by the level of its homogeneity exceeds hypHSH as a medicine manufactured by Serano (Italy) and genHSH as a medicine manufactured by Kabi Vitrum (Sweden).